Results 51 to 60 of about 84,234 (301)

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission.
A. Flint, B. Meyers, A. Rothschild, Ellen M. Whyte, G. Alexopoulos, M. Rudorfer, Patricia Marino, Samprit Banerjee, C. Pollari, Yiyuan Wu, A. Voineskos, B. Mulsant   +11 more
semanticscholar   +1 more source

Bilateral Basal Ganglion Hemorrhage after Severe Olanzapine Intoxication

Case Reports in Psychiatry, 2020
Olanzapine is a second-generation antipsychotic drug which is generally considered safe with well therapeutic antipsychotic effects. We describe a patient suffering from bilateral intracerebral hemorrhage after severe olanzapine intoxication without ...
Kerstin Schweyer, Bastian Fatke, Kornelia Kreiser, Christian Rabe, Christian Seifert, Benno Ikenberg   +5 more
doaj   +1 more source

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomised controlled treatment trials [PDF]

, 2006
Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory.
Carey, P, Denys, D, Fineberg, N, Premkumar, P, Seedat, S, Sivakumaran, T, Stein, DJ, Vythilingum, B, Westenberg, H   +8 more
core   +1 more source

Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance

Scientific Reports, 2019
Olanzapine is a second-generation anti-psychotic drug used to prevent neuroinflammation in patients with schizophrenia. However, the long-term administration of olanzapine leads to insulin resistance (IR); the mechanisms of this effect remains poorly ...
Hu-qun Li, Shiyong Peng, Shihong Li, Shouqing Liu, Yifan Lv, Ni Yang, Liangyu Yu, Yahui Deng, Zhongjian Zhang, Mao-sheng Fang, Yunxiang Huo, Ying Chen, T. Sun, Weiyong Li   +13 more
semanticscholar   +1 more source

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Neuropsychiatric Disease and Treatment, 2021
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894.
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D   +9 more
doaj  

Metformin and berberine prevent olanzapine-induced weight gain in rats. [PDF]

PLoS ONE, 2014
Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain.
Yueshan Hu, Alan J Young, Erik A Ehli, Dustin Nowotny, Paige S Davies, Elizabeth A Droke, Timothy J Soundy, Gareth E Davies   +7 more
doaj   +1 more source

Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients - Results from an experimental study [PDF]

, 2003
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation.
Kagerer, S., Möller, Hans-Jürgen, Soyka, Michael, Winter, C.   +3 more
core   +1 more source

Psychiatric manifestations of multiple sclerosis and acute disseminated encephalomyelitis [PDF]

, 2006
It is unusual for acute disseminated encephalomyelitis and multiple sclerosis to present as purely psychiatric disorders. We report five patients with such demyelinating diseases and symptoms of psychosis, depression or anxiety.
Brinar, Marko, Brinar, Vesna V., Habek, Mario, Poser, Charles M.   +3 more
core   +1 more source

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

Neuropsychiatric Disease and Treatment, 2019
Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied antipsychotics, resulting in a considerable amount of clinical data across diverse ...
L. Citrome, J. McEvoy, M. Todtenkopf, D. McDonnell, P. Weiden   +4 more
semanticscholar   +1 more source

Beyond the pill: New medication delivery options for ADHD [PDF]

, 2017
Successful treatment of pediatric disorders has necessitated the development of alternative medication formulations, as children may prefer alternative dosage forms to tablets or capsules.
Cutler, Andrew J, Mattingly, Gregory W
core   +2 more sources